
OSE Immunotherapeutics SA
PAR:OSE

OSE Immunotherapeutics SA
Research & Development
OSE Immunotherapeutics SA
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
OSE Immunotherapeutics SA
PAR:OSE
|
Research & Development
-€23.5m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
![]() |
Valneva SE
PAR:VLA
|
Research & Development
-€67.8m
|
CAGR 3-Years
26%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-12%
|
|
![]() |
Nanobiotix SA
PAR:NANO
|
Research & Development
-€41.2m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-20%
|
|
G
|
Genfit SA
PAR:GNFT
|
Research & Development
-€29.7m
|
CAGR 3-Years
9%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
![]() |
Inventiva SA
PAR:IVA
|
Research & Development
-€99.8m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
![]() |
Eurobio Scientific SA
PAR:ALERS
|
Research & Development
-€5.7m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
1%
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

See Also
What is OSE Immunotherapeutics SA's Research & Development?
Research & Development
-23.5m
EUR
Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Research & Development amounts to -23.5m EUR.
What is OSE Immunotherapeutics SA's Research & Development growth rate?
Research & Development CAGR 5Y
-3%
Over the last year, the Research & Development growth was 17%. The average annual Research & Development growth rates for OSE Immunotherapeutics SA have been 11% over the past three years , -3% over the past five years .